Women With Ovarian Cancer and With Fertility Preservation: A Survival Analysis Using the Surveillance, Epidemiology, and End Results Database and Construction of Nomograms to Predict Cancer-Specific Survival

Yue-min Hou, Hui Yu, Jia-tao Hao, Fang Feng and Rui-fang An*

Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Objective: This study aimed to determine the risk and prognostic factors of ovarian cancer (OC) in women having fertility-sparing surgery, as well as survival outcomes of those with stage I epithelial ovarian cancer (EOC). We also determined the effect of chemotherapy in OC treatment and used multiple independent risk factors to establish a prognostic nomogram model for patients with stage I EOC.

Patients and Methods: Individuals with OC and with fertility-sparing surgery (FSS) between 1998 and 2016 were identified in the SEER database. Univariate and multivariate logistic regression was performed to identify the distributions of patient characteristics according to chemotherapy. Cancer-specific survival (CSS) was assessed using Kaplan–Meier curves and log-rank tests. Univariate and multivariate Cox regression was conducted to determine the independent prognostic factors for CSS. Cox analysis was used to construct a nomogram model. The C-index and calibration plots showed the performance evaluation results.

Results: A total of 1,839 women with OC with FSS were identified in the SEER database. Factors associated with significantly higher odds of undergoing chemotherapy included younger age, being unmarried, having grades 2–4, stages II–III, or clear cell and non-epithelial histologic type following a multivariate logistic regression analysis. Multivariate Cox regression analysis confirmed that age, marital status, chemotherapy, histologic type, grade, and the International Federation of Gynecology and Obstetrics (FIGO) stage were independent prognostic factors for CSS. In stage I EOC, the prognosis in patients with stage IA/IB-grade 3 (5-year CSS 85.3%) or stage IC (5-year CSS 80.6%) was worse than that in those with stage IA/IB-grade 1 (5-year CSS 95.2%), or stage IA/IB-grade 2 (5-year CSS 94.7%). However, chemotherapy improved the survival of patients with stage IA/IB-
INTRODUCTION

Ovarian cancer (OC) is one of the most common gynecological malignancies and ranks as the fifth cause of death from cancer among women in the United States. Epithelial ovarian cancer (EOC) is most commonly diagnosed among women of post-menopausal age (1). According to the latest cancer statistics in the United States in 2021, 13,770 individuals died of OC and 21,410 are newly diagnosed with (2). The surgery and chemotherapy treatment of OC are based on the International Federation of Gynecology and Obstetrics (FIGO) staging (3, 4), but the 5-year relative survival rate (RSR) is below 50%.

For younger women, this means loss of reproductive potential (5). The American Society of Clinical Oncology (ASCO) recommends preserving fertility in women of reproductive age when treating gynecologic tumors other than cervical cancer (6). For example, patients with endometrial cancer (EC) can be treated by oral or intra-uterine progestins with or without hysteroscopic endometrial resection to preserve fertility. In recent years, there were also studies on preoperative biopsy technique and the postoperative recurrence predictor of EC, which increase the possibility of pregnancy in women with preserved fertility (7, 8).

Although the National Comprehensive Cancer Network (NCCN) guidelines recommend fertility-sparing surgery (FSS) only for early-stage patients or those with low-risk ovarian tumors (9), these recommendations are based on limited observational evidence (10). One study reported increased provision of FSS in younger vs. older women with no difference in mortality (11). For older women, complete surgical staging may result in decreased quality of life and distress and negatively impact survivorship (12). Therefore, some women without evidence of extra-pelvic disease may consider FSS. Currently, data on OC in women with FSS are limited, while chemotherapy for it is controversial (13). The Surveillance, Epidemiology, and End Results (SEER) database is a cancer database in the United States that has collected information on 34.6% of the American population from 18 different registries. Here, we analyzed the SEER database to determine clinical characteristics and related factors in women with preserved fertility according to chemotherapy. Odds ratios (OR) and 95% confidence intervals (CI) were reported from the logistic regression. Univariate and multivariate Cox regression analyses were employed to identify independent predictors associated with survival by reporting the hazard ratios (HR) and 95% CI. Nomograms were constructed from the predictive model that includes identified prognostic factors. The predictive accuracies of the constructed nomograms were evaluated using the concordance index (C-index). Calibration was done to assess the consistency between the predicted probability and the actual result. Survival comparisons were made using Kaplan–Meier analysis and log-rank tests.

Therefore, we established a nomogram model for stage I EOC patients with FSS based on findings from the SEER database.

MATERIALS AND METHODS

Data Source and Study Population

All the primary data were acquired from the SEER database. The SEER+Stat version 8.3.9 (https://seer.cancer.gov/seerstat/) was used to screen eligible patients who were 18–40 years old with histologically confirmed primary OC (ICD-O-3, C56.9) between 1998 and 2016. We gathered the following information: age at diagnosis, race, grade, historic stage, tumor-node-metastasis (TNM) stage, FIGO stage, marital status [other (separated, divorced, widowed)], surgery treatment (unilateral salpingo-oophorectomy and uterus-sparing), chemotherapy, pathological subtype [Third Edition (ICD-O-3) morphology codes (8441/3, 8442/3, 8460/3, 8461/3, 8462/3, 9014/3 for serous; 8380/3, 8381/3, 8382/3 for endometrioid; 8005/3, 8310/3 for clear cell; 8470/3, 8471/3, 8472/3, 8480/3, 8482/3 for mucinous)], vital status, and survival time. Patients diagnosed by autopsy or death certificate, had multiple tumors or distant metastases, and with a follow-up shorter than 6 months, were excluded from the study. A total of 1,839 patients were eligible for incidence analysis. The primary endpoint was cancer-specific survival (CSS). CSS was defined as the time interval from OC diagnosis to OC-related death (Figure 1).

Statistical Analysis

Univariate and multivariate logistic regression was conducted to determine clinical characteristics and related factors in women with fertility preservation according to chemotherapy. Odds ratios (OR) and 95% confidence intervals (CI) were reported from the logistic regression. Univariate and multivariate Cox regression analyses were employed to identify independent predictors associated with survival by reporting the hazard ratios (HR) and 95% CI. Nomograms were constructed from the predictive model that includes identified prognostic factors. The predictive accuracies of the constructed nomograms were evaluated using the concordance index (C-index).
Statistical analyses were all performed using SPSS (version 22.0, IBM Corporation, USA) and R software (version 3.6.3; www.r-project.org/). A two-sided p value <0.05 was considered statistically significant.

RESULTS

Patient Characteristics
The demographic and clinical characteristics of the 1,839 patients are shown in Table 1. Most of them were 18–30 years old (59.3%), White (72.9%), with localized stage (80.4%), unmarried (57.2%), with non-epithelial histologic type (59.2%), with grade 1 (31.8%), T1 (85.4%), N0 (98.0%), and stage I (84.3%). A total of 628 (34.1%) patients received chemotherapy and 1,211 (65.9%) did not. There was an equal number of White patients in both chemotherapy and non-chemotherapy groups. Women with younger, non-localized stage, unmarried, clear cell and non-epithelial histologic type, grades 2–4, T2–3, N1, M1, and stages II–III were more likely to receive chemotherapy.

Determinants of Chemotherapy
Table 2 shows the distributions of patient characteristics according to chemotherapy treatment using univariate and multivariate logistic regression. On the multivariate logistic regression analysis, younger age was associated with higher odds of undergoing chemotherapy (vs. 31–40 years old, OR: 0.737, 95% CI: 0.582–0.932). Whereas compared to married patients, unmarried (OR:1.581, 95% CI: 1.240–2.019) patients were associated with higher odds of undergoing chemotherapy. Additionally, compared to patients with serous histologic type, those with clear cell histologic type (OR: 3.047, 95% CI: 1.405–6.608) and non-epithelial histologic type (OR: 3.103, 95% CI: 1.955–5.084) had higher odds of undergoing chemotherapy. Also, compared to patients with grade 1, those with grade 2 (OR: 2.642, 95% CI: 1.956–3.580), grade 3 (OR: 4.560, 95% CI: 3.371–6.198), or grade 4 (OR: 2.722, 95% CI: 1.690–4.371) had higher odds of chemotherapy. Further, patients with stage II (OR: 1.529, 95% CI: 1.067–2.180) and stage III (OR: 3.765, 95% CI: 2.498–5.750) had higher odds of chemotherapy compared to those with stage I.

Predictors for Survival
In the univariate analysis, age, marital status, histology type, chemotherapy, grade, and FIGO stage were all associated with survival. The multivariate Cox regression model showed that patients with chemotherapy (HR: 0.351, 95% CI: 0.221–0.558) and non-epithelial histologic type (HR: 0.238, 95% CI: 0.138–0.412) had better outcomes compared with the former. Additionally, poor outcomes were seen in patients who were older (HR: 1.777, 95% CI: 1.196–2.640), separated, divorced, or widowed (HR: 2.344, 95% CI: 1.374–3.999) or had grade 3 (HR: 2.923, 95% CI: 1.707–5.004), grade 4 (HR: 7.065, 95% CI: 3.645–13.696), stage II (HR: 7.098, 95% CI: 4.633–10.874), or stage III (HR: 9.882, 95% CI: 6.120–15.958) compared with the former (Table 3).

Survival Outcomes in Stage I EOC
Analysis of Kaplan–Meier curves in stage I EOC indicated that significant differences were seen in CSS between stage IA/IB and stage IC (5-year CSS 92.8% vs. 80.6%) (Figure 2A). Similarly, significant differences were detected in CSS between stage IA/IB-grade 2 and stage IA/IB-grade 3 (5-year CSS 94.7% vs. 85.3%) (Figure 2C). Significant differences were seen in CSS between stage IA/IB-grade 2 and stage IC (5-year CSS 94.7% vs. 80.6%) (Figure 2D). However, no significant differences were detected in CSS between stage IA/IB-grade 1 and stage IA/IB-grade 2 (Figure 2B). Moreover, no significant statistical differences were in CSS between stage IA/IB-grade 3 and stage IC (Figure 2E).

Stratification analyses were carried out to control for confounders. CSS curves stratified by chemotherapy are shown in Figure 3. In stratification analysis according to FIGO stage and grade, significant differences were seen in CSS when patients...
were stage IA/IB-grade 3 (5-year CSS 78.1% vs. 94.6%), but not when they were stage IA/IB-grade 1, stage IA/IB-grade 2, or stage IC between non-chemotherapy and chemotherapy groups in EOC (Figures 3A–D).

Construction of a Nomogram Model of CSS for Stage I EOC

We made a nomogram model of CSS by significant factors among patients of stage I EOC. Each variable could be evaluated with a score from 0 to 100, and the corresponding sum of these scores ranging from 0 to 240 was also assessed accordingly based on the 3-, 5-, and 10-year survival rates varying from 0.1% to 0.9% (Figure 4).

Calibration Chart Among Patients With Stage I EOC

The C-index was 0.771 among women with stage I EOC. To further evaluate the consistency of the nomogram, we drew a calibration plot to describe a favorable prediction for 3-year (A) and 5-year (B) CSS among patients with fertility preservation (Figure 5).

**DISCUSSION**

OC is one of the most common gynecological malignancies. The increasing number of young patients with OC, and the need to preserve their reproductive function during treatment, is essential. In our study, we report the clinical and prognostic characteristics of FSS of patients with OC. Due to the growing interest in FSS in early-stage EOC, we analyzed the survival outcomes of patients with stage I EOC and the role of chemotherapy in it. From this, a prognostic nomogram for stage I EOC was established to allow clinicians to individualize treatment.

Chemotherapy is often used to treat OC (14, 15), and this study demonstrates that it is an independent prognostic factor for CSS in patients. However, chemotherapy has effects on ovarian function, such as reproductive toxicity (16–18). In this study, the multivariate logistic regression indicated that younger women who are unmarried and have grades 2–4, stages II–III, clear cell, or non-epithelial histologic types had higher odds associated with chemotherapy, which is similar to previous
TABLE 2 | Univariate and multivariate logistic regression for associations between patient characteristics and chemotherapy.

| Variable | Univariate | Multivariate |
|----------|------------|--------------|
|          | OR (95% CI) | p-value | OR (95% CI) | p-value* |
| Age      |            |         |            |         |
| 18–30    | 1 (reference) |          | 1 (reference) |          |
| 31–40    | 0.565 (0.461–0.691) | <0.001 | 0.737 (0.582–0.932) | 0.011 |
| Race     |            |         |            |         |
| White    | 1 (reference) |          | 1 (reference) |          |
| Black    | 1.007 (0.751–1.342) | 0.961 |            |          |
| Other    | 1.040 (0.784–1.372) | 0.785 |            |          |
| Marital status |            |         |            |         |
| Married  | 1 (reference) |          | 1 (reference) |          |
| Unmarried| 1.828 (1.484–2.259) | <0.001 | 1.581 (1.240–2.019) | <0.001 |
| Other    | 0.917 (0.566–1.447) | 0.717 | 0.925 (0.549–1.516) | 0.762 |
| Histology|            |         |            |         |
| Serous   | 1.612 (0.993–2.678) | 0.058 | 1.689 (1.003–2.908) | 0.053 |
| Clear cell| 2.857 (1.398–5.842) | 0.004 | 3.047 (1.405–6.608) | 0.005 |
| Mucinous | 1.153 (0.702–1.934) | 0.580 | 1.409 (0.826–2.452) | 0.216 |
| Non-epithelial| 2.675 (1.751–4.224) | <0.001 | 3.103 (1.955–5.084) | <0.001 |
| Grade    |            |         |            |         |
| 1       | 1 (reference) |          | 1 (reference) |          |
| 2       | 2.150 (1.618–2.862) | <0.001 | 2.642 (1.956–3.580) | <0.001 |
| 3       | 4.673 (3.509–6.251) | <0.001 | 4.560 (3.371–6.198) | <0.001 |
| 4       | 3.079 (1.961–4.822) | <0.001 | 2.722 (1.690–4.371) | <0.001 |
| FIGO    |            |         |            |         |
| I       | 1 (reference) |          | 1 (reference) |          |
| II      | 1.460 (1.040–2.037) | 0.027 | 1.529 (1.067–2.180) | 0.020 |
| III     | 4.152 (2.861–6.101) | <0.001 | 3.765 (2.498–5.750) | <0.001 |

*pBold P-value, p<0.05.

studies (19–21). It is understandable that in younger and unmarried women with OC, having children may not be an urgent concern, so they opt for chemotherapy to prevent tumor recurrence. Moreover, one study indicated no association between chemotherapy and decreased fertility in young patients with EOC (22). Also, chemotherapy was the best choice for women with advanced or high-grade OC to prevent recurrence after FSS. In addition, we found that women with OC with a clear cell and non-epithelial histologic type were more likely to undergo chemotherapy. This may be because non-epithelial OC occurs more often in young women, and FSS in non-epithelial OC is not limited by FIGO stage (23). A retrospective study has shown that OC patients with a clear cell histologic type who received chemotherapy had better outcomes, some studies have shown that even among patients with stage I clear cells, FSS does not increase the risk of relapse or shorten survival compared with radical surgery (28–30). At present, there is some controversy about chemotherapy for patients with stage I EOC. One study showed that there was no significant difference in DFS and OS between patients with stage I A and IB based on chemotherapy status. However, in patients with intraoperative tumor capsule rupture, DFS in a chemotherapy group was significantly better than that in a non-chemotherapy group (24). According to the NCCN guidelines, observation is an option for patients with stage I, because it has not been demonstrated that chemotherapy provides clear clinical benefit in patients with survival >90% with surgical treatment alone or in patients with low-risk cancer types (9). Our research showed that the prognosis in patients with stage IA/IB-grade 3 or stage IC was worse than those with stage IA/IB-grade 1 or stage IA/IB-grade 2. In addition, significant differences were seen in CSS when patients were stage IA/IB-grade 3 between non-chemotherapy and chemotherapy groups. Although no significant differences were seen when patients were stage IC,
TABLE 3 | Univariate and multivariate Cox regression of cancer-specific survival among OC women with FSS.

| Variable           | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value* |
| **Age**            |                     |         |                     |         |
| 15–30              | 1 (reference)       |         | 1 (reference)       |         |
| 31–44              | 2.681 (1.887–3.805) | <0.001  | 1.777 (1.196–2.640) | 0.004   |
| **Race**           |                     |         |                     |         |
| White              | 1 (reference)       |         | 1 (reference)       |         |
| Black              | 0.884 (0.522–1.499) | 0.647   |                     |         |
| Other              | 0.992 (0.607–1.620) | 0.974   |                     |         |
| **Marital status** |                     |         |                     |         |
| Married            | 1 (reference)       |         | 1 (reference)       |         |
| Unmarried          | 0.955 (0.656–1.390) | 0.811   | 1.299 (0.862–1.957) | 0.211   |
| Other              | 3.555 (1.138–5.909) | <0.001  | 2.344 (1.374–3.999) | 0.002   |
| **Histology**      |                     |         |                     |         |
| Serous             | 1 (reference)       |         | 1 (reference)       |         |
| Endometrioid       | 0.606 (0.368–0.996) | 0.048   | 0.883 (0.529–1.476) | 0.636   |
| Clear cell         | 1.615 (0.862–3.026) | 0.135   | 1.705 (0.881–3.299) | 0.113   |
| Mucinous           | 0.384 (0.223–0.663) | 0.001   | 0.801 (0.450–1.425) | 0.450   |
| Non-epithelial     | 0.134 (0.081–0.222) | <0.001  | 0.238 (0.138–0.412) | <0.001  |
| **Chemotherapy**   |                     |         |                     |         |
| No                 | 1 (reference)       |         | 1 (reference)       |         |
| Yes                | 0.448 (0.290–0.692) | <0.001  | 0.351 (0.221–0.558) | <0.001  |
| **Grade**          |                     |         |                     |         |
| 1                  | 1 (reference)       |         | 1 (reference)       |         |
| 2                  | 2.124 (1.296–3.479) | 0.003   | 1.603 (0.966–2.661) | 0.068   |
| 3                  | 2.565 (1.539–4.241) | <0.001  | 2.923 (1.707–5.004) | <0.001  |
| 4                  | 5.689 (3.061–10.574)| <0.001  | 7.065 (3.645–13.696)| <0.001  |
| **FIGO**           |                     |         |                     |         |
| I                  | 1 (reference)       |         | 1 (reference)       |         |
| II                 | 5.015 (3.326–7.560) | <0.001  | 7.098 (4.633–10.874)| <0.001  |
| III                | 9.989 (6.487–15.380)| <0.001  | 9.882 (6.120–15.958)| <0.001  |

*Bold P-value, p<0.05.

FIGURE 2 | Kaplan–Meier curves for CSS in stage I EOC. (A) Stage IA/IB vs. stage IC, (B) stage IA/IB-grade 1 vs. stage IA/IB-grade 2, (C) stage IA/IB-grade 2 vs. stage IA/IB-grade 3, (D) stage IA/IB-grade 2 vs. stage IC, and (E) stage IA/IB-grade 3 vs. stage IC.
we found that chemotherapy improved the survival of patients to some extent.

In addition, a prognostic nomogram model was established for patients with stage I EOC. The nomogram exhibits excellent performance in the results of the calibration and the C-index. The exact score concerning each factor was represented by an elegant graphical interface, and patients being 30–40 years old, with grade 4, with stage IV, being separated, divorced, or widowed, under...
non-chemotherapy, and with clear cell histology contributed to high scores.

However, a limitation of this study included insufficient information in the SEER database on regimens and the number of cycles of chemotherapy. Also, the SEER database is a registry in the United States, and potential biases are unavoidable.

In conclusion, chemotherapy was often given to fertility-sparing women who are younger, unmarried, with grades 2–4, or with clear cell and non-epithelial histologic type. In addition, those older-aged, separated, divorced, or widowed, with grades 3–4, or with stages II–III were correlated with increased risks of CSS in OC. Further, this study suggests that in EOC, patients with stage IA/IB-grade 1 or stage IA/IB-grade 2 can be followed up without chemotherapy, while those with stage IA/IB-grade 3 and stage IC may need chemotherapy for improved survival.

**DATA AVAILABILITY STATEMENT**

All the primary data were acquired from the SEER database (https://seer.cancer.gov/seerstat/).

**ETHICS STATEMENT**

The informed consent was not required in this study, because personal identifying was not included in the SEER database.

**AUTHOR CONTRIBUTIONS**

Study concept and design: R-fA. Data acquisition: Y-mH, FF. Data analysis and interpretation: Y-mH, HY. Software: J-tH. Manuscript preparation: Y-mH. Critical revision: R-fA. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

The authors appreciate the SEER database for providing high-quality clinical data for our research and AiMi Academic Services (www.aimieditor.com) for the English language editing and review services.
REFERENCES

1. National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. Available at: https://seer.cancer.gov/statfacts/html/ovary.html (Accessed February 20, 2019).

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654

3. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary Chemotherapy Versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. Lancet (2015) 368(9509):249–57. doi: 10.1016/S0140-6736(14)62223-6.

4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer (2009) 115(6):1234–44. doi: 10.1002/cncr.21419

5. Carter J, Rowland K, Chi D, Brown C, Abu-Rustum N, Castiel M, et al. Gynecologic Cancer Treatment and the Impact of Cancer-Related Infertility. Gynecol Oncol (2005) 97(1):90–5. doi: 10.1016/j.ygyno.2004.12.019

6. Loren AW, Mang J, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2013) 31(19):2500–10. doi: 10.1200/JCO.2013.49.2678

7. Di Spieazio Sardo A, De Angelis MC, Della Corte L, Carugno J, Zizzioli B, Guadagni E, et al. Should Endometrial Biopsy Under Direct Hysteroscopic Visualization Using the Grasp Technique Become the New Gold Standard for the Preoperative Evaluation of the Patient With Endometrial Cancer? Gynecol Oncol (2020) 158(2):347–53. doi: 10.1016/j.ygyno.2020.05.012

8. Raffone A, Catena U, Travaglini A, Masciullo V, Spadola S, Della Corte L, et al. Mismatch Repair-Deficiency Specifically Predicts Recurrence of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma After Conservative Treatment: A Multi-Center Study. Gynecol Oncol (2021) 161(3):795–801. doi: 10.1016/j.ygyno.2021.03.029

9. Armstrong DK, Alvarez RD, Bakkum-Gamze JN, Barroilhet L, Berchuck A, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2021) 19(2):191–226. doi: 10.6004/jnccn.2021.0007

10. Santos ML, Pais AS, Almeida Santos T. Fertility Preservation in Ovarian Cancer Patients. Gynecol Endocrinol (2012) 27(6):483–9. doi: 10.1080/0951390.2012.1087234

11. Melamed A, Rizzo AE, Nitecki R, Gockley AA, Bregar AJ, Schorge JO, et al. All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Multicenteric Comparative Study Using Inverse Probability of Treatment Weighting. Obstet Gynecol (2017) 130(1):71–9. doi: 10.1097/AOG.0000000000002102

12. Doll KM, Pinheiro LC, Reeve BB. Pre-Diagnosis Health-Related Quality of Life, Surgery, and Survival in Women With Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer (2009) 115(6):1234–44. doi: 10.1002/cncr.21419

13. Bergamini A, Ferrandina G, Candotti G, Taccagni G, Scarfone G, Bocciolone L, et al. Stage I Juvenile Granulosa Cell Tumors of the Ovary: A Multicentre Study. Gynecol Oncol (2018) 152(2):346–52. doi: 10.1016/j.ygyno.2018.11.032

14. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact. Future Oncol (2016) 12(20):2333–4. doi: 10.2217/fon-2016-0176

15. Cho HW, Lee S, Min KI, Hong JH, Song YJ, Lee JK, et al. Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity. Int J Mol Sci (2020) 21(20):7972. doi: 10.3390/ijms21207972

16. Del-Pozo-Lérida S, Salvador C, Martínez-Soler F, Tortosa A, Peruchó M, Giménez-Bonafe P. Preservation of Fertility in Patients With Cancer (Review). Oncol Rep (2019) 41(5):2607–14. doi: 10.3892/orn.2019.7063

17. Blumenfeld Z. Chemotherapy and Fertility. Best Pract Res Clin Obstet Gynaecol (2012) 26(3):379–90. doi: 10.1016/j.bpcogyn.2011.11.008

18. Kohn JR, Katebi Kashi P, Acosta-Torres S, Beavis AL, Christianson MS. Fertility-Sparing Surgery for Patients With Cervical, Endometrial, and Ovarian Cancers. J Minim Invasive Gynecol (2021) 28(3):392–402. doi: 10.1016/j.jmig.2020.12.027

19. Stanbridge KJ, Childrens C. Ovarian Conservation in Management of Pediatric Gynecology Malignancies. Curr Opin Obstet Gynecol (2018) 30(5):316–25. doi: 10.1097/GCO.0000000000000484

20. Crafston SM, Cohn DE, Llamocca EN, Louden E, Rhoades J, Felix AS. Fertility-Sparing Surgery and Survival Among Reproductive-Age Women With Epithelial Ovarian Cancer in 2 Cancer Registries. Cancer (2020) 126(6):1217–24. doi: 10.1002/cncr.36260

21. Floyd JL, Campbell S, Rauh-Hain JA, Woodard T. Fertility Preservation in Women With Early-Stage Gynecologic Cancer: Optimizing Oncologic and Reproductive Outcomes. Int J Gynecol Cancer (2021) 31(3):345–51. doi: 10.1136/ijgc-2020-001176

22. Ceppi L, Galli F, Lamanna M, Magni S, Dell’Orto F, Verri D, et al. Ovarian Function, Fertility, and Menopause Occurrence After Fertility-Sparing Surgery and Chemotherapy for Ovarian Neoplasms. Gynecol Oncol (2019) 152(2):346–52. doi: 10.1016/j.ygyno.2018.11.032

23. Yang B, Yu Y, Chen J, Zhang Y, Yin Y, Yu N, et al. Preservation of Fertility in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Natl Compr Canc Netw (2021) 19(2):191–226. doi: 10.6004/jnccn.2021.0007

24. Nasioudis D, Mulugeta-Gordon L, McMinn E, Frey MK, Chapman-Davis E, Holcomb K. Fertility Sparing Surgery for Patients With FIGO Stage I Clear Cell Ovarian Carcinoma: A Database Analysis and Systematic Review of the Literature. Int J Gynecol Cancer (2020) 30(9):1372–7. doi: 10.1136/ijgc-2020-001716

25. Kajiyama H, Yoshikawa M, Tamauchi S, Yoshikawa N, Suzuki S, Kikka K. Fertility-Sparing Surgery for Young Women With Ovarian Endometrioid Carcinoma: A Multicentric Comparative Study Using Inverse Probability of Treatment Weighting. Eur J Obstet Gynecol Reprod Biol (2019) 248:101. doi: 10.1016/j.ejogrb.2019.07.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hou, Yu, Hao, Feng and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The copyright, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.